GLP-1 Receptor Agonists Beyond Diabetes and Weight: What an Umbrella Review of 60 Meta-Analyses Reveals

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed the treatment landscape for type 2 diabetes and obesity. But as millions of patients worldwide take medications like semaglutide and tirzepatide, a critical question looms: what are these peptide-based drugs doing to the body beyond blood sugar control and weight loss?

A sweeping umbrella review published in JAMA Network Open in March 2026 offers the most comprehensive answer yet.¹

The Study at a Glance

Yang et al. conducted a systematic search across PubMed, Web of Science, Embase, Scopus, and the Cochrane Database through January 2026, identifying 60 meta-analyses that covered 116 unique noncardiometabolic health outcomes. These meta-analyses collectively spanned 1,751 randomized clinical trials with approximately 3.58 million participants.

The study populations primarily involved people with type 2 diabetes (71.7%) and obesity (33.3%), with follow-up periods ranging from 3 months to 5.4 years or longer.

Key Findings

Gastrointestinal Adverse Events: The Known Trade-Off

The most consistent signals confirmed what clinicians already observe in practice. GLP-1 RAs were associated with significantly higher odds of:

• Nausea: OR 2.47 (95% CI 1.84–3.34) — high-quality evidence
• Vomiting: OR 2.78 (95% CI 1.91–4.06) — moderate-quality evidence
• Diarrhea: OR 1.94 (95% CI 1.52–2.49) — high-quality evidence

These findings align with the well-documented mechanism of GLP-1 RAs slowing gastric emptying and modulating gut-brain signaling.

A Surprising Protective Signal Against Infections

Perhaps the most intriguing finding was a potential protective association against serious infections (OR 0.89, 95% CI 0.87–0.92), supported by high-quality evidence. A suggestive association with reduced respiratory disease risk was also observed (OR 0.85, 95% CI 0.80–0.92).

This is particularly noteworthy given that GLP-1 receptors are expressed on immune cells, and preclinical data have suggested anti-inflammatory properties of GLP-1 signaling.¹

Biliary Events and Other Signals

Gallbladder or biliary disease showed elevated odds (OR 1.34, 95% CI 1.16–1.55), but the authors noted this did not meet stringent credibility thresholds and should be considered exploratory. The same caution applies to several other outcomes evaluated across gastrointestinal, cancer, fracture, neurologic, psychiatric, hepatic, and endocrine domains.

What This Means for Peptide Therapeutics

This umbrella review underscores both the promise and complexity of GLP-1-based peptide therapies. The potential protective effects against infections add to a growing body of evidence suggesting these peptides have systemic immunomodulatory properties that extend well beyond their original indications.

However, the authors were careful to note that evidence for most noncardiometabolic outcomes was of lower certainty, and the protective signals require confirmation in dedicated clinical trials before they can inform clinical decision-making.

For the peptide research community, this review serves as a reminder that as peptide therapeutics reach hundreds of millions of patients, understanding their full biological footprint becomes increasingly urgent.

---

Source: Yang K, Liu C, Guo Q, Li Y. GLP-1 Receptor Agonists and Noncardiometabolic Outcomes: An Umbrella Review of Meta-Analyses. JAMA Netw Open. 2026;9(3):e264722. doi:10.1001/jamanetworkopen.2026.4722

Footnotes

1. Yang K, Liu C, Guo Q, Li Y. GLP-1 Receptor Agonists and Noncardiometabolic Outcomes: An Umbrella Review of Meta-Analyses. JAMA Netw Open. 2026;9(3):e264722. PMID: 41915388 ↩ ↩²